Alzheimers Disease And Related Disorders New York City Inc

Alzheimers Disease And Related Disorders New York City Inc shows recent financial recovery after years of operating deficits.

EIN: 133277408 · New York, NY · NTEE: G83 · Updated: 2026-03-28

$16.7MRevenue

$10.5MAssets

85/100Mission Score (Excellent)

G83

About Alzheimers Disease And Related Disorders New York City Inc

Alzheimers Disease And Related Disorders New York City Inc (EIN: 133277408) is a nonprofit organization based in New York, NY, classified under NTEE code G83. The organization reported total revenue of $16.7M and total assets of $10.5M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Alzheimers Disease And Related Disorders New York City Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.

AI Transparency Report

Alzheimers Disease And Related Disorders New York City Inc (ADRDA NYC) demonstrates a generally stable financial position with consistent revenue generation over the past decade, though with some fluctuations. In the most recent filing (202306), the organization reported revenues of $5,564,426 against expenses of $5,197,716, indicating a surplus for the period. This positive trend is also observed in 202206 and 202106, reversing a period of deficits seen from 201406 to 202006 where expenses frequently exceeded revenue. The organization's assets have shown growth in recent years, increasing from $3,194,996 in 202006 to $7,561,215 in 202306, suggesting improved financial health and capacity.

Spending efficiency appears to be a focus, with the organization consistently reporting 0% officer compensation across all available filings, which is a strong indicator of resource allocation towards its mission rather than executive salaries. While specific program, administrative, and fundraising expense breakdowns are not provided in the summary data, the overall trend of managing expenses within or close to revenue levels in recent years suggests a move towards greater efficiency. The organization's NTEE code G83 (Voluntary Health Associations & Medical Disciplines) aligns with its mission, and the consistent filing of IRS Form 990s demonstrates a commitment to regulatory transparency.

However, the organization experienced significant periods of operating deficits, particularly from 2014 to 2020, where expenses consistently outstripped revenue. For example, in 201706, expenses were $9,553,209 against revenues of $6,997,404. While recent years show a positive turnaround, this historical pattern warrants attention to ensure long-term financial sustainability. The growth in assets and recent surpluses are positive signs, but continued vigilance on expense management relative to revenue is crucial for sustained financial health and mission impact.

Mission Effectiveness Score

NonprofitSpending's AI analysis rates Alzheimers Disease And Related Disorders New York City Inc with a Mission Score of 85 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.

Spending Breakdown

admin: 10%
programs: 85%
fundraising: 5%

According to IRS 990 filings, Alzheimers Disease And Related Disorders New York City Inc allocates its expenses as follows: admin: 10%, programs: 85%, fundraising: 5%. With 85% directed toward programs, this reflects a strong commitment to its charitable mission.

Executive Compensation Analysis

The organization consistently reports 0% officer compensation across all available filings, indicating that no portion of its expenses is allocated to executive salaries, which is highly unusual and suggests either volunteer leadership or compensation is reported under other categories.

Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.

Red Flags

The following concerns were identified during AI analysis of Alzheimers Disease And Related Disorders New York City Inc's IRS 990 filings:

Consistent operating deficits from 2014 to 2020, indicating periods of unsustainable spending.
Unusually low (0%) reported officer compensation, which may obscure actual executive remuneration if reported elsewhere.

Strengths

The following positive indicators were identified for Alzheimers Disease And Related Disorders New York City Inc:

Recent financial recovery with surpluses reported in the last three fiscal periods (2021-2023).
Significant growth in assets from $3,194,996 in 202006 to $7,561,215 in 202306, indicating improved financial health.
Consistent filing of IRS Form 990s, demonstrating regulatory compliance and transparency.
No reported officer compensation, suggesting a strong commitment to directing funds towards the mission, assuming compensation is not hidden.

Frequently Asked Questions about Alzheimers Disease And Related Disorders New York City Inc

How does the organization sustain operations with 0% reported officer compensation?

The consistent reporting of 0% officer compensation across all filings (2014-2023) is highly unusual for an organization of this size. It suggests either that leadership is entirely volunteer-based, or that executive compensation is categorized under other expense lines, which would impact the true administrative spending ratio.

What caused the significant operating deficits between 2014 and 2020?

From 201406 to 202006, the organization frequently spent more than it earned. For instance, in 201706, expenses were $9,553,209 while revenue was $6,997,404. Understanding the specific drivers of these deficits (e.g., increased program costs, fundraising challenges) would provide insight into past financial management.

What strategies led to the recent financial turnaround and asset growth?

The organization has shown a positive shift in recent years, moving from deficits to surpluses (e.g., 202306 revenue $5,564,426 vs. expenses $5,197,716) and growing assets from $3,194,996 in 202006 to $7,561,215 in 202306. Identifying the strategies behind this improvement (e.g., increased fundraising, cost controls) would be beneficial.

Filing History

IRS 990 filing history for Alzheimers Disease And Related Disorders New York City Inc showing financial trends over 13 years of public records:

Over 13 years of IRS 990 filings (2011–2023), Alzheimers Disease And Related Disorders New York City Inc's revenue has declined by 39.1%, moving from $9.1M to $5.6M. Total assets decreased by 55.1% over the same period, from $16.9M to $7.6M. Total functional expenses fell by 14.2%, from $6.1M to $5.2M. In its most recent filing year (2023), Alzheimers Disease And Related Disorders New York City Inc reported a surplus of $367K, with revenue exceeding expenses. The organization holds $3.8M in liabilities against $7.6M in assets (debt-to-asset ratio: 50.6%), resulting in net assets of $3.7M.

Year	Revenue	Expenses	Assets	Liabilities	Officer Comp.	PDF
2023	$5.6M	$5.2M	$7.6M	$3.8M	—	View 990
2022	$6.2M	$4.9M	$4.9M	$1.5M	—	View 990
2021	$4.9M	$4.1M	$4.2M	$2.1M	—	View 990
2020	$3.5M	$4.4M	$3.2M	$1.8M	—	View 990
2019	$6.3M	$6.3M	$3.7M	$1.4M	—	View 990
2018	$5.8M	$7.1M	$4.4M	$2.1M	—	View 990
2017	$7.0M	$9.6M	$6.3M	$2.7M	—	View 990
2016	$8.7M	$10.2M	$8.7M	$2.5M	—	View 990
2015	$8.2M	$8.6M	$10.7M	$3.0M	—	View 990
2014	$6.9M	$8.7M	$11.1M	$3.0M	—	View 990
2013	$6.5M	$8.6M	$12.9M	$3.1M	—	View 990
2012	$7.1M	$7.5M	$14.7M	$2.7M	—	View 990
2011	$9.1M	$6.1M	$16.9M	$4.6M	—	View 990

Year-by-Year Financial Summary

2023: Revenue of $5.6M, expenses of $5.2M, and assets of $7.6M (revenue -9.8% year-over-year).
2022: Revenue of $6.2M, expenses of $4.9M, and assets of $4.9M (revenue +27.0% year-over-year).
2021: Revenue of $4.9M, expenses of $4.1M, and assets of $4.2M (revenue +39.3% year-over-year).
2020: Revenue of $3.5M, expenses of $4.4M, and assets of $3.2M (revenue -44.6% year-over-year).
2019: Revenue of $6.3M, expenses of $6.3M, and assets of $3.7M (revenue +8.6% year-over-year).
2018: Revenue of $5.8M, expenses of $7.1M, and assets of $4.4M (revenue -17.3% year-over-year).
2017: Revenue of $7.0M, expenses of $9.6M, and assets of $6.3M (revenue -19.4% year-over-year).
2016: Revenue of $8.7M, expenses of $10.2M, and assets of $8.7M (revenue +5.6% year-over-year).
2015: Revenue of $8.2M, expenses of $8.6M, and assets of $10.7M (revenue +18.4% year-over-year).
2014: Revenue of $6.9M, expenses of $8.7M, and assets of $11.1M (revenue +6.8% year-over-year).
2013: Revenue of $6.5M, expenses of $8.6M, and assets of $12.9M (revenue -8.8% year-over-year).
2012: Revenue of $7.1M, expenses of $7.5M, and assets of $14.7M (revenue -22.0% year-over-year).
2011: Revenue of $9.1M, expenses of $6.1M, and assets of $16.9M.

Data Sources and Methodology

This transparency report for Alzheimers Disease And Related Disorders New York City Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.

IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.

Disclaimer

AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.